Paul van Damme

Paul Joseph van Damme currently works at Ontario Genomics Institute, as Director, Wildlaw Capital Markets, Inc., as Managing Director, and WD Capital Markets, Inc., as Managing Director.
Mr. van Damme also formerly worked at Quest PharmaTech, Inc., as Independent Director from 2012 to 2015, ZipLocal, Inc., as Chief Financial Officer & Director from 2012 to 2016, Insception Biosciences, Inc., as Director, Structural Genomics Consortium, as Chief Financial Officer, Secretary & Director from 2012 to 2019, Ontario Genomics Institute (Private Equity), as Director, XORTX Pharma Corp., as Director, OncoQuest, Inc., as Director from 2015 to 2020, XORTX Therapeutics, Inc., as Independent Director from 2018 to 2026, Aptose Biosciences, Inc., as Chief Financial Officer from 2004 to 2005, Vasogen, Inc., as CFO in 2007, Bradmer Pharmaceuticals, Inc., as Chief Financial Officer from 2007 to 2018, Allelix Biopharmaceuticals, Inc., as Chief Financial Officer, NXA, Inc., as Chief Financial Officer, Crosswinds Holdings, Inc., as Chief Financial Officer from 2013 to 2015, PricewaterhouseCoopers, Inc., as Principal, Laidlaw, Inc. (Connecticut), as Chief Financial Officer, Definium Therapeutics, Inc., as Chief Financial Officer from 2019 to 2020, Canada Systems Group Ltd., as Chief Financial Officer in 1991, Junior Achievement of Central Ontario, as Chief Financial Officer, Ellipsiz Communications Ltd., as Chief Financial Officer from 2011 to 2015, and Galaxy Digital Holdings, Inc., as Chief Financial Officer.
Mr. van Damme received his Masters Business Admin degree from Rotman School of Management and undergraduate degree from the University of Toronto.